ralfinamide (NW-1029) / Newron  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ralfinamide (NW-1029) / Newron
NCT01019824 / 2008-006176-30: Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Completed
3
411
Europe
Ralfinamide
Newron Pharmaceuticals SPA, Parexel, CliniRx
Pain
05/10
08/11
2008-006159-39: A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF TWO FIXED DOSES OF RALFINAMIDE (160 OR 320 MG/DAY) IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN

 
3
30
Europe
Ralfinamide, NW-1029,
Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS
Chronic neuropathic low back pain
 
06/10

Download Options